Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) EBT (2016 - 2025)

Dexcom (DXCM) has disclosed EBT for 16 consecutive years, with $340.7 million as the latest value for Q4 2025.

  • Quarterly EBT rose 61.24% to $340.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 53.51% year-over-year, with the annual reading at $1.1 billion for FY2025, 53.51% up from the prior year.
  • EBT for Q4 2025 was $340.7 million at Dexcom, down from $352.3 million in the prior quarter.
  • The five-year high for EBT was $352.3 million in Q3 2025, with the low at $6.4 million in Q4 2021.
  • Average EBT over 5 years is $157.8 million, with a median of $150.2 million recorded in 2022.
  • The sharpest move saw EBT crashed 95.85% in 2021, then soared 1981.25% in 2022.
  • Over 5 years, EBT stood at $6.4 million in 2021, then skyrocketed by 1981.25% to $133.2 million in 2022, then surged by 84.83% to $246.2 million in 2023, then dropped by 14.18% to $211.3 million in 2024, then soared by 61.24% to $340.7 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $340.7 million, $352.3 million, and $241.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.